Latigo Biotherapeutics IPO: offering terms from its S-1
Latigo Biotherapeutics priced its IPO at $18 a share on 7 Aug 2026 and raised $346 million. Its shares trade on Nasdaq as LTGO.
Headlines
- Net loss, 2025
- $109M
- IPO price
- $18
- $346M raised
Latigo Biotherapeutics IPO terms
From the final prospectus (424B4).
- Exchange
- The Nasdaq Global Select Market
- Ticker
- LTGO
- IPO price
- $18
- Shares offered
- 19,200,000
- Raised
- $346M
- Registered
- $331M, the amount the filing fee is paid on
- Underwriters
- Goldman Sachs & Co. LLC, Jefferies, Leerink Partners and Guggenheim Securities
- First filed
- 17 Jul 2026
Latigo Biotherapeutics revenue and profit
| Period | Revenue | Operating income | Net income |
|---|---|---|---|
| 2025 | - | -$110M | -$109M |
| First quarter of 2026 | - | -$23M | -$23M |
Latigo Biotherapeutics share structure and company facts
- Employees
- 59
- Headquarters
- Thousand Oaks, California
Latigo Biotherapeutics shares since the IPO
Latest close 26 Oct 2026
- IPO price
- $18
- Priced 7 Aug 2026
- First close
- $18.25
- +1% on the IPO price
- Latest close
- $15.26
- -15% on the IPO price
Latigo Biotherapeutics's IPO filings
The registration statement, each amendment and the final prospectus, oldest first.
About the data
- Terms and financials are read from Latigo Biotherapeutics's newest prospectus (424B4 filed 7 Aug 2026) by a Kadoa workflow. Check figures that matter against the filing.
- Registered is the amount the filing fee is paid on, often a placeholder before the price range is set.
- Raised is the IPO price times the shares sold, without the underwriters' option. Trading compares the first and latest close with the IPO price.